Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...
Leerink, however, has questioned the company’s direction. In a note to clients sent out Jan. 8, the analysts said they ...
In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments ...
The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz (A16z). | The ...
It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...
Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...
After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital ...
Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...
Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the ...
AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback